DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma
About this trial
This is an interventional treatment trial for Diffuse Large B Cell Lymphoma
Eligibility Criteria
Inclusion Criteria:
Histological confirmed aggressive B-cell lymphoma with one of the following subtypes:
diffuse large B-cell lymphoma, NOS with at least one poor prognostic factor as follows:
- aaIPI 2~3(≤60 years) or IPI 3~5(>60 years);
- double protein expression lymphoma(IHC MYC≥40% and BCL2≥50%) with Ann Arbor stage of III~IV or aaIPI 2~3 or IPI 3~5;
- CD5+ DLBCL.
- high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements;
- high-grade B-cell lymphoma, NOS
- transformed lymphoma(no prior treatment)
- Age 18 to 65 years
- ECOG-PS: 0~2
- Life-expectancy > 3 months
Exclusion Criteria:
- Patients with central nerves system involvement
- HIV positivity
Sites / Locations
- Hunan Cancer Hospital
- the First Affiliated Hospital of Nanchang University
- the First Affiliated Hospital of Jilin University
- the Second Hospital of Dalian Medical University
- Qingdao Central Hospital
- Institute of Hematology & Blood Diseases HospitalRecruiting
Arms of the Study
Arm 1
Experimental
DLCL002 protocol
Patients will receive R-DA-EDOCH(rituximab, etoposide, dexamethasone, vincristine, cyclophosphamide, doxorubicin) as induction therapy and be evaluated by PET CT after the fourth cycle. Patients achieve CR at interim-PET will receive either ASCT or the remaining 4 cycles of R-DA-EDOCH, while those achieve PR(Deauville score 4-5) will be rescued by two courses of R(2)-DHAP(rituximab, lenalidomide(only for patients with non-GCB DLBCL), dexamethasone, cisplatin, cytarabine). Patients who achieved CR+good PR(Deauville score 4) after the rescue therapy will be consolidated with ASCT,and those remain in PR(Deauville score 5) will receive other rescue treatments.